text:
Best Practices for Getting Things Done — Weekly Review
A newer version of this post is now published at: GTD Basics – Methods for Reflecting and Weekly Reviews in LifeTopix.
LifeTopix and My.Agenda are personal organization apps for iPad, iPhone, and iPod touch. Both apps are especially useful for those who utilize David Allen's Getting Things Done® (GTD) method. The GTD method is an excellent method for organizing your life and getting things done for both life and business.
We're constantly incorporating features that are useful for GTD, and we enjoy sharing our best practices for using these features. In this post, I'll show you how you can use LifeTopix's features for the Weekly Review phase of GTD. Keep in mind that our starter App, My.Agenda, can include many of the features discussed by purchasing the Get Things Done Pack as an in-app purchase.
What is GTD?
If you're not familiar with GTD, it's "the groundbreaking work-life management system by David Allen that provides concrete solutions for transforming overwhelm and uncertainty into an integrated system of stress-free productivity," according to David Allen's website. Allen lays out five key phases of the GTD process, which include 1) Capture/Collect, 2) Process, 3) Organize, 4) Review, and 5) Do. This post focuses on the Review phase of this workflow. In earlier blog posts, I've described the first four phases. At the end of this post, you'll find links to those earlier posts.
What is the Review Phase in GTD?
In many productivity systems including GTD, experts recommend that you set aside time every week for approximately an hour to reflect on the items that you've completed, determine what needs to be completed the following week, and to contact people who you need to connect with. Allen recommends that you select a consistent place and time so you develop a habit for your Weekly Review. Schedule your Weekly Reviews on your LifeTopix calendar to ensure your process remains consistent.
The following table provides an overview of the items that you should include in your Weekly Review and how LifeTopix provides a feature or view to make the Weekly Review painless.
|Weekly Review Checklist
|LifeTopix Feature or View
|Calendar (Time Sensitive Items) ->
|Calendar / Agenda View
|Email and Someday/Maybe Items ->
|Quick Inbox
|Projects ->
|Tasks + Projects Topic
|Contacts ->
|People + Services Topic (or) Context Tags
|Checklists and To-do Lists ->
|Notes + Files Topic or Agenda view
|"Waiting for" and Catch All ->
|Context Tags and Recently Updated
|Loose Papers ->
|Box, Dropbox, SkyDrive, Google Drive Integration
How Do You Review These Items in LifeTopix?
LifeTopix and My.Agenda are both very flexible apps so there are several ways that you can approach your Weekly Review. The following sections describe different approaches for viewing the items you wish to review.
Calendar / Agenda (Time Sensitive Items)
Items you've placed on your calendar are important for your Weekly Review because they're time sensitive. You've given them a date for a reason, whether it's a hard deadline, meeting, or other event.
When performing your Weekly Review, review the items that you've scheduled and create any new items that might be a result of your scheduled items. For example, you might have a meeting with a client coming up, but you haven't reviewed your client's requirements. Put this prep time on your calendar or use your LifeTopix Quick Inbox to collect this information.
LifeTopix Calendar
The LifeTopix Calendar is an essential tool for your Weekly Review. Looking ahead 30 days will give you a good "big picture" view of your scheduled items. Make sure that your daily tasks are aligned to your strategic initiatives.
LifeTopix's Month view is very handy for reviewing time-sensitive items. Review the next two to three weeks to get a sense of what is immediately ahead of you. The image below shows an example of the calendar with the Month view selected. The calendar shows a clear marker on each day that you've scheduled an item. You can filter the calendar to view the types of items that are important to you. For example, if you want to view tasks, but not media items — this is certainly possible.
LifeTopix Agenda View
You'll find your Agenda view to be priceless during your Weekly Review. The Agenda view provides you with an easy-to-read, high-level view of the items that you've scheduled for the current day and the next seven days. It also includes your to-do lists, checklists, overdue items, and undated items. Just like the calendar, it includes filters so you can decide which types of items you wish to view on your agenda. The image below shows an example of the Agenda view.
Review your to-dos, overdue items, and upcoming items on your calendar. The Undated items section is especially useful because they may not be on your radar yet. This is a good time to decide the fate of your upcoming undated items, tasks, projects, events, and other items.
Email and Someday/Maybe Items (Quick Inbox)
Utilize the LifeTopix Quick Inbox for items without a clear due date, with a due date in the future (ticklers), that you've collected from your email messages, or that you wish to do someday (such as learn to speak another language). These items should be reviewed during your Weekly Review. Quickly review items in your someday/maybe lists to determine if you want to convert them to projects or other items. Remove any items that are no longer of interest to you.
The image below shows an example of items waiting to enter the Processing Phase in the LifeTopix Quick Inbox.
In LifeTopix, it's easy to convert these items to actionable items such as projects, tasks or events, as shown in the following image.
Projects (Tasks + Projects Topic)
In GTD or other productivity systems, a project is an objective that requires one or more actions. The Weekly Review is a good time to determine what you need to accomplish to move your projects forward and the due dates for the tasks or other items associated with the project.
In LifeTopix, you can create tasks (as task lists) or as a part of a project in the LifeTopix Tasks + Projects topic. These tasks can remain undated if you wish, and you should review them regularly. In LifeTopix, you can create general projects, education projects, health and activity projects, and other types of projects. You can review them all in one place — the Tasks + Projects topic, which is shown below.
Once you tap on any project, you can view and associate additional items, such as a task list, to-do lists, checklists, appointments, files, notes, expenses, services, shopping items, etc. The project gives you a complete picture of each project and organizes all associated items.
Contacts (People + Services Topic)
During your Weekly Review, you should decide if you need to contact friends, family, or colleagues regarding projects, tasks or other items. Your Weekly Review is a good time to manage your follow-ups. In LifeTopix, when you create tasks or other items, you can assign a contact as an "owner" as shown in the image below:
During your Weekly Review, in the LifeTopix People + Services topic, you can view all your recent activity in the "Recent Items" section and easily identify any owners that you've assigned to items, as shown in the image below:
Tapping View/Edit in the screen above enables you to easily view the assignments for this person, as shown in the image below:
You can also easily contact your selected person via phone, SMS, Twitter, and Facebook through the Person view, which makes follow-ups a breeze.
Checklists and To-do Lists (Notes + Files Topic or Agenda View)
During your Weekly Review, it's a good idea to review your to-do lists and checklists. I usually reserve to-do lists for lists of items that can be completed fairly quickly and checklists for things such as packing lists. You can view checklists and to-do lists directly from the Agenda view, shown earlier in this post, or you can manage these lists directly from the Notes + Files topic, as shown in the following image.
Tapping on the tile that shows your to-do list or checklist allows you to view it and check off completed items.
Context Tags
One of the most powerful features of LifeTopix is the implementation of tags. In LifeTopix, Context tags are multi-purpose tags used for the purpose of identification of items. With tags, you can label items for identification or to give GTD Context. When items are tagged with matching Contexts, you can define your own views with your defined groupings.
In the GTD method, Contexts are typically based on a physical location, resource, or the equipment that's necessary to complete a task. Examples of Contexts are @office, @home, @grocery store, @computer, @train, @vacation, or @phone. Also, in GTD, items are allowed more than one Context. For example, you could assign a Context of @office and @phone for phone calls that are completed at the office.
One way that you can identify items that you wish to include in your weekly review is to tag items with a tag defined as @Review. In LifeTopix, you can use multiple tags on items; therefore, you can implement GTD Contexts, and you can use tags to flag items for review. The image below shows an example of how this appears in LifeTopix:
LifeTopix enables you to tag several types of items including:
- Topic Items: Asset, Event, Gift, Note, Person, Project, Service, Service Provider, Shopping Items, Shopping List, Subject, Trip, Visit
- Data Items: Appointment, Audio, Bookmark, Checklist, Drawing, Expense, File, Photo, Reminder, Task, Video
- Log Items: Activity, Health Stat, Medication, Nutrition, Wellness
Tagging Items
One strategy you can utilize is to be cognizant of projects, tasks, and other items you want to include in your Weekly Review and tag them when appropriate. For example, if there's a document that you plan to review by the end of the week, tag it with @Review.
In GTD, Waiting For is the list of items that you cannot complete because you're blocked in some way. For example, your TPS report may be due; however, you're waiting for the new cover sheet. Consequently, you would tag it with @Waiting For. This way, you will make sure to follow up on these items before they become overdue. You can tag items with context tags, such as @Assistant, @Boss, or @Spouse for items that you've delegated or are waiting for an answer before you can proceed.
In LifeTopix, you can apply your tags to any of the items listed above by simply tapping Edit in the appropriate screen for the item, such as a task. The image below shows one method for tagging an item. In this example, the item is a task.
When you perform your Weekly Review, you'll save time because you can view all your items that you've tagged with @Review or other tags in one place, as shown below.
This view gives you full access to your items with editing capabilities and allows you to view the items by Type, Updated, or Name. You can modify due dates, priority, effort; remove items that are no longer required; and mark items complete — there are several options based on the type of item that you're modifying.
Keep mind, if you don't believe you have the discipline to tag your items with @Review throughout the week, LifeTopix includes many other options for organizing your Weekly Review — don't fret!
Loose Papers – Online File Integration
The Weekly Review is a good time to pull out any of your loose papers that you've gathered during the week. LifeTopix supports access to files and notes in Box, Dropbox, Google Drive, SkyDrive, Evernote, and Toodledo and also supports media files such as photos and video. We recommend that you digitize your files, store the files in the Cloud, and access those files via your LifeTopix items.
More Information
GTD is a great system for managing your busy home and work life. If you'd like to know more about best practices using LifeTopix for GTD, refer to the following posts:
Best Practices for Getting Things Done — Prioritizing Tasks in LifeTopix
Best Practices for Getting Things Done with LifeTopix Categories and Contexts
Best Practices for Getting Things Done — Capture and Collect
Best Practices for Getting Things Done — Processing
Best Practices for Getting Things Done — Master Organizing
Best Practices for Getting Things Done — Doing Phase
Your Turn
We enjoy hearing from you. Please share your best practices for using LifeTopix.
GTD® and Getting Things Done® are registered trademarks of the David Allen Company. LightArrow Apps are not affiliated with or endorsed by the David Allen Company.


text:
Take the tour through rock and pop cultures final decade of the 20th century with Stiflers Mom Armed with attitude, style and killer
performance, this band is musical adrenaline that spellbinds you from the very first downbeat. From No Doubt and Pearl Jam through Spice
Girls and B.I.G., Its 10 years of greatest hits wrapped up into one solid evening. Each show comes complete with stage props, costume
changes, movie clips, and 90s soundbytes. Add on the Band Camp horn section, and youve got a crew that puts an original spin on all
the slammin rock and pop tunes from the 90s.

subset: commoncrawl


text:
Home The CaDCR directory
Join a pro-ana group or start your own website. Anything that will keep you motivated. 28. Make an ANA scrapbook with pics of skinny models. The anorexic diet has been gaining a lot of popularity these days because of some amazingly working pro ana tips and tricks which have been revealed.
Find new year 2019 Stock Images in HD and millions of other royalty-free stock photos, illustrations, and vectors in the Shutterstock collection. Thousands of Happy New Year 2019 Quotes Greetings, Images, Quotes, Wishes available for you and your family


text:
You are about to enter a website that may contain content of an adult nature.
Hello everyone, this is black cam girl BustyDora here. I'm 40 year old Female speak English in the ebony live sex chat action. I`m an unstoppable Sex-Machine. I can do the craziest things You dreamed about. Get on board and forgot about world existing around You - this is going to be another dimension. Let me be Your tour guide on this journey. Cute young men who are a bit afraid of me. We will work it out, believe me;. I am sexy, busty hot mature lady ready to play with my tight pussy and bouncing tits, naughty but also innocent, wild and sensual, come to see my perfect huge and natural breasts, my round ass, my sexy legs .... The idea of f*cking in public places makes me extremely crazy! The fear of being noticed excites me the most. Would you would like to catch me or better still be caught with me. Hello there! I just love role play, the brain is t is my expertise and also what I will do in private black sex cam show. I have Blue eyes, Short Blonde hairs and my measurements are 98-68-96. For Turn ons: I can`t resist men who know how to treat a lady like me, tease and pamper me. Be sure - I`ve got what You need, visit my private room and You will get everything You`ve been dreaming about.. For TurnsOff: I am OK with cheap people but what turns me off is being treated cheap. Respect me & in return I will do all I can to make your dreams come true.. If you prefer kinks, then Shaved, are mine. I'm just hungry for a HARD cock, can't wait to see u at my ebony sex chat room! :)
This website contains ebony webcam strip, ebony webcam porn and ebony chat related sexually explicit content.
You must be at least 18 years of age to enter this website.
© Since 2012 ebonycamsplus.com Ebony Cams Network All Rights Reserved
AllHosts1 - AllHosts2 - AllHosts3 - AllHosts4 - AllHosts5 - AllHosts6 - AllHosts7 - AllHosts8 - AllHosts9 - AllHosts10 - AllHosts11 - AllHosts12


text:
"Alco" Surname
Frequency of "Alco" Surname in the US
2000 US Census
The surname "Alco" is not included in the US Census Bureau's ranking of surnames with 100 or more people. Since fewer than 100 people with this surname were included in the 2000 Census, it is relatively uncommon.
Source: "Frequently Occurring Surnames from the Census 2000", US Census Bureau.
"Alco" Graves on Histopolis
Histopolis currently has 0 grave(s) with the surname "Alco".
Resource Links for "Alco"
Sorry, there are currently no resource links for the surname "Alco".
Do you know of a web page containing information about this surname that would be useful to genealogy or history researchers? Please add it now! (Free registration required)
Surnames that Sound Like "Alco"
The surname "Alco" has a Soundex code of A420. The following 180 surname(s) may sound similar to "Alco" since they share the same Soundex code.
Unconfirmed Surname
Histopolis has an entry for this surname but it might be the result of an error in the source information, since:
- It was not listed in the US Census Bureau list of most frequent surnames for either 1990 or 2000,
- Histopolis currently has few entries (0) for this surname in the Histopolis Grave Index, and
- There are no currently no links to other sites with this surname.
To confirm this surname, add a link (above) to a page with information about this surname or that references individuals with this surname.


text:
June 4th, 2015
The Executive Leadership Council recently issued a press release announcing its support for The NAACP Legal Defense Fund's call for the federal government to enact nationwide policing reforms. Both organizations believe such reform must include federal legislation related to increasing Department of Justice (DOJ) oversight of funding for police department training and strengthening the DOJ's Civil Rights Division's ability to identify and investigate patterns of discrimination and misconduct that can potentially surface at police departments across the country.
Given this week's media attention on related issues, including a House Appropriations Committee effort to provide less funding than requested for law enforcement initiatives such as the proposal to fund nearly 50,000 police body cameras, as well as other high profile incidents in the media, we thought it was timely to re-post the link to our press release supporting the LDF's efforts.
ELC Members Hold 2019 Winter Meeting in San Diego
March 13th, 2019
Your Vote Matters
November 1st, 2018
The Relationship Business
October 23rd, 2018
Think It. Build It. Own It. How my leadership potential was ignited at the 24th Annual Executive Leadership Council Mid-Level Managers' Symposium
Being Your Own Best Advocate
October 19th, 2018
Photo Snapshot: The ELC's 2018 Recognition Gala
October 16th, 2018
The ELC Hosts a Networking Reception and Open House During CBC Week 2018
September 25th, 2018
Photo Snapshot: The 2018 Summer Executive Workshop – Black Economic Forum on Martha's Vineyard
August 20th, 2018
The ELC Commemorates 15th Anniversary of the Women's Leadership Forum
August 3rd, 2018
Price M. Cobbs Took His Book on Black Anger Into Executive Offices
July 6th, 2018
Children of Color: What is Their Value in Today's America?
June 26th, 2018
A Satisfying Summer Meeting Staged in Seattle
June 12th, 2018
The Power of Inclusive Leadership
May 30th, 2018
Courageous Leadership in the C-Suite: The ELC Supports Starbucks
April 24th, 2018
I Have A Dream. 50 Years On... by ELC Member Trevor Phillips
April 9th, 2018
#MeetSkipSpriggs: Learn More About The ELC's New President & CEO on Social Media
April 4th, 2018
ELC Members Lead Discussion on Corporate Inclusion and Promotion of Black Executive Talent in the UK at the Women of the World Festival in London
March 21st, 2018
Record Turnout for The ELC's 2018 Winter Meeting in Miami
March 12th, 2018
Bringing Your Authentic Self to Work as a Black Woman – Unpacked
March 7th, 2018
Embracing the Call of Duty
November 14th, 2017
TIAA Hosts The ELC's Q4 CBI Event in Charlotte Focused on Strengthening HBCU Boards and Public-Private Partnerships
Photo Snapshot: The ELC's 2017 Recognition Gala
October 31st, 2017
ELC Post-Summer Activities Ramp Up Before Gala
October 3rd, 2017
The ELC hosts its first Regional Women's Leadership Forum in New York
September 19th, 2017
Be the Advocate of Your Own Strengths
September 13th, 2017
National Association of Black Journalists is supported by The ELC
September 1st, 2017
The ELC hosts Leadership Development Week East in Miami, FL
August 29th, 2017
Statement From ELC President & CEO on ELC Member Kenneth C. Frazier
August 16th, 2017
The ELC Hosts the 2017 Women's Leadership Forum in Chicago
July 24th, 2017
The ELC Visits Capitol Hill to Advocate for Diversity, Inclusion and HBCUs
July 21st, 2017
The ELC Concludes the 2017 London Convening Marking the First-Ever ELC Membership Meeting in the UK
June 20th, 2017
British Ambassador hosts special reception for The ELC
May 31st, 2017
ELC Members Gather in Houston for the 2017 Winter Meeting
March 8th, 2017
The Executive Leadership Council Recognizes Our 2016 ELC Ambassador Companies
January 17th, 2017
Orlando Ashford Named Chair of The Executive Leadership Council
January 11th, 2017
Ebony Power 100 Celebrates the World's Most Inspiring African-Americans
December 1st, 2016
Photo Snapshot: The ELC's 30th Anniversary Recognition Gala
November 14th, 2016
Grainger Hosts The ELC's 2016 Q4 Corporate Board Initiative Event featuring Chairman James T. Ryan
October 18th, 2016
Capital One Hosts The ELC's Q3 CBI Event Focused on Board Member Compensation
September 20th, 2016
Expanding Globally with The Executive Leadership Council
July 28th, 2016
The ELC Hosts 2016 Women's Leadership Forum in Philadelphia Ahead of the Democratic National Convention
July 26th, 2016
ELC Member Roger Ferguson Becomes First African American to Join Alphabet Board of Directors
July 7th, 2016
ELC Members Join Panel on Executive Leadership at the 2016 ESSENCE Festival in New Orleans
July 6th, 2016
Detroit: The City of Opportunity
June 15th, 2016
James A. Bell Motivates Black Executives Interested in Corporate Board Service
April 25th, 2016
Twitter Hosts The ELC's 2016 Q1 Corporate Board Initiative Event
March 8th, 2016
ELC President & CEO Ronald Parker Discusses Corporate Board Diversity with Bloomberg Radio
February 25th, 2016
The ELC's 2016 Winter Meeting in Los Angeles Challenges Members to Network and Think BIGGER
February 22nd, 2016
CBI 4Q Panel Hosted By DuPont Dives Deep Into Regulatory Boards
November 23rd, 2015
ELC Member Brett J. Hart Named Acting CEO for United Continental Holdings, Inc.
October 20th, 2015
It's PERSONAL: Reflections from the 2015 ELC Recognition Gala
October 16th, 2015
Photo Snapshot: The ELF Annual Recognition Gala
October 15th, 2015
PwC Chairman and Senior Partner Robert Moritz Pens Blog on Diversity Referencing The Executive Leadership Council White Paper on 21st Century Global Leadership
October 5th, 2015
Three Leading Global Black Organizations Unite to Support Black Leadership During CBC Week
September 21st, 2015
Carnival Hosts The ELC's 2015 Q3 Corporate Board Initiative Event
September 18th, 2015
The Executive Leadership Council Unveils White Paper on 21st Century Global Leadership
September 15th, 2015
The Executive Leadership Foundation Announces Honorees for Annual Awards Gala
September 14th, 2015
"Exploring the World of Private Equity" on Martha's Vineyard
August 20th, 2015
The ELC's Institute Director Highlights Successes from the 2015 Leadership Development Week
August 19th, 2015
Here's What You Missed from The ELF's 2015 Women's Leadership Forum
July 24th, 2015
United Kingdom…African Diaspora…United States…Brothers & Sisters…Communities of Impact…
July 23rd, 2015
Photo Snapshot: The ELC's Visit to London
July 2nd, 2015
The Executive Leadership Council Concludes Its First International Membership Meeting in Toronto
June 19th, 2015
ELC Supports The Legal Defense Fund's Call For Police Reform
Four ELC Members Appointed to Corporate and University Boards in May 2015
May 28th, 2015
What's Trending in Private Equity: Oversubscribed Funds
May 13th, 2015
Google Hosts The ELC's 2015 Q1 Corporate Board Initiative Event
April 1st, 2015
Members Meet in Middleburg for 2015 Winter Meeting
March 18th, 2015
ELC Members on the Move
February 25th, 2015
C-SPAN Hosts a Week-Long TV Series Featuring Interviews with 8 Top HBCU Presidents
February 17th, 2015
Media Draws Attention to Decline of Black CEOs
February 3rd, 2015
ELC Chair Carla Harris Visits the TODAY Show to Promote Her Latest Book
February 2nd, 2015
ELC COO Brickson Diamond Featured in Washington Post Article on Lack of Diversity in Hollywood
January 8th, 2015
Congressman G. K. Butterfield Takes the Reins of Leadership for CBC
January 7th, 2015
ELC Member Rosalind Hudnell Addresses Need for Minority Engineers in New York Times Article
Winter 2014 Edition of Contact is Here
December 18th, 2014
It's Time To Revolutionize Race Relations
December 5th, 2014
Watch the Gala!
October 30th, 2014
ELC Leadership Participates in Congressional Black Caucus 44th Annual Legislative Conference
October 6th, 2014
ELC Member Howard Woolley Published in NACD Magazine
September 12th, 2014
ELC Members in the News and On the Move
September 8th, 2014
ELC's Bernard J. Tyson Named No. 2 Most Influential Person in Healthcare
August 27th, 2014
2014 Women's Leadership Forum
August 6th, 2014
Leadership Development Week - REGISTRATION ENDS June 20!
June 19th, 2014
The International Connection…the New Black America
June 11th, 2014
Embarking Upon Our Journey From "Good to Great"
June 4th, 2014
View Blog Archive


text:
Start the New Year right by organizing your accessories & make-up!
This year you won't have to go crazy looking for that one eye liner you need or that one handbag that matches your outfit.
We have found some amazing organizing DIY'S so you can find everything easily this year.
1. Frame
2. Sheet Metal
3. Material
4. Tacky Spray
5. Scissors
6. Magnets
7. Hot Glue Gun
Step 1: Tacky Spray the material over the sheet metal.
(You can leave uncovered for a cool metallic look.)
Step 2: Place the sheet metal in frame
Step 3: Hot glue the magnets onto the back of your makeup essentials.
Step 4: Hang up the frame and your magnetized make up. Done!
Photo & DIY Credit by ThreadSence
- 1 wooden utensil holder (Bed, Bath, and Beyond)
- 4 packs of Small Solid Brass Screw Eyes (5/8 inch)
- 3 packs of Solid Brass Cup Hooks (5/8 inch)
- 1 Picture hanger set
1. Mark where you want to put your screws. You can put two in each column (for necklaces), and as many as you could fit in the smaller horizontal shelves (for earrings). You can use a ruler if you'd like to space them out evenly.
2. Twist all of the screws into place. Use an ice pick or a bigger screw to start each hole. If your hands are sweaty or shaky, try using a paper towel to get a better grip on the screws as you're twisting. Push down hard so they really go in and go slowly with a steady hand.
A glass of wine is recommended.
3. Attach the picture holder. On the back of your jewelry organizer, twist the two screws in towards the top and evenly spaced out in the center. Secure the wire by twisting it around itself. Cut with pliers.
4. Spray paint! Go outside and put newspaper down. Follow the directions on the can and let dry.
5. Hang it to the wall, add your jewelry, and you're done!
Photo & DIY Credits by Color Me Blue
1. SHELVES : To keep clutches in place, file them like books. Use sweater dividers to cordon off and protect bags made of delicate materials like satin (which can snag) and patent (which can dent and discolor). Lynk shelf dividers, $7 each, bedbathandbeyond.com
2. HOOKS: To keep bags from sagging under their own weight and losing their shape (a danger when they're left lying down), hang them from hooks affixed to the top of your storage space or unit. Liberty Hardware single-prong hooks, $5 each, amazon.com
3. CREDENZA: While this concept works happily in a closet, we love seeing all our bags displayed in an open case like this one. White low rider bookcase, $349, landofnod.com
Dress up a plain bookcase with molding: This finishing touch makes a room—and your bag collection—feel extra special.
Photo & Article via Lucky Magazine


text:
- 1 Enhancements
- 2 Features
Enhancements are: 1. Less documented improvements to a Fedora release which do follow the feature process and do not fit the feature definition below. 1. Added to the release summary by anyone under heading of Other Enhancements. The release summary for each release lives in the following namespace: http://fedoraproject.org/wiki/Releases/<release number>/ReleaseSummary
Definition of a Feature
A feature is defined as a significant change or enhancement to the version of Fedora currently under development that may or may not include new packages.
Features are usually considered to meet one or more of the following objectives:
1. highly user visible changes 1. improvements or changes that require non-trivial cross-package integration 1. exciting new capabilities we can trumpet fedora having--some of this is good public relations. Some examples might include: a. work Fedora contributors are doing upstream as part of their work for Fedora a. new features from upstream that we are making available in the Fedora for the first time a. improvements that are Fedora specific. Example from past releases include the Core and Extras Merge and smolt 1. significant enough that if not completed properly or without a proper backup plan could delay the release 1. noteworthy enough to call out in the release notes
Feature Process
Individual features are tracked on separate wiki pages in the Features/ namespace. Individual features are organized using categories.
[[Image:Features_Policy_Overview: [[Image:Features_Policy_feature-process-flow.png] Source: File:Features Policy feature-process-flow.odg
1. New feature ideas may be added at any time to the wiki
- Features/FeatureName (CategoryProposedFeature)
1. New feature desired for a particular release are designated as such
- Features/FeatureName (CategoryProposedFedoraX)
1. Proposed feature is presented to FESCo for acceptance a. Accepted features move to CategoryAcceptedFedoraX a. Denied features remain in CategoryProposedFedoraX for rework or future resubmission a. After Feature Freeze all features in CategoryProposedFedoraX move to CategoryProposedFeature where they can be proposed for the next Fedora release. 1. Periodic status 1. Important milestones
New Feature Ideas
Community members are encouraged to create new pages for features that enhance or improve Fedora. Anyone can propose new features for Fedora by following these steps: 1. Add a new wiki page to http://fedoraproject.org/wiki/Features/<YourFeatureName> 1. Add details for each of the sections using the template at Template as a guide. 1. Add CategoryProposedFeature to the bottom of the wiki page.
Proposing Official Features
In order to be considered an official feature accepted for the next Fedora release, the feature should be formally documented on a separate wiki page which includes the following information:
1. Summary of the feature 1. A designated owner (with a link to contact information http://fedoraproject.org/wiki/<YourName> --including a valid email address). The owner is responsible for: a. Making sure the feature is completed according to the schedule a. Communicating periodic status a. Attending feature status meetings 1. Current status a. last updated a. Estimated percentage of completion 1. Description of the new feature a. Detailed explanation of what the new feature will do and how it will be implemented 1. Benefit to Fedora 1. Scope 1. Test Plan 1. Dependencies--on other packages or features 1. Contingency plan 1. Link to documentation 1. Important information for release notes
Feature Acceptance
Acceptance by FESCo is a sanity check, presumed in most cases to be a formality, to ensure that new features compliment Fedora's guidelines and is manageable, prior to publicizing as officially targeted for the next release.
Feature acceptance is agreement by FESCo that a particular feature is: 1. consistent with the goals and policies of Fedora while within the laws governing the corporate entity sponsoring Fedora--Red Hat. 1. supported by the Fedora leadership. 1. suitable for listing as an Official Feature of the next release of Fedora 1. important to track prior to feature freeze and could affect timeliness of release
1. The Feature Owner adds the feature page to CategoryProposedFedoraX 1. The Feature Wrangler reviews page for completeness and raises for review at next FESCo meeting 1. FESCo reviews individual feature pages and votes to approve or deny the feature.
- More than 50% of voting FESCo members must be in agreement to approve or deny.
- The feature owner or proxy should be in attendance at this FESCo meeting to answer questions or provide clarification.
1. After a FESCo vote the Feature Wrangler: 1. Adds accepted features to the accepted category (CategoryAcceptedFedoraX) 1. Moves the feature to CategoryProposedFeature unless they so violate the practices of Fedora that they should be removed. We would expect an event like this to be highly unusual)
Periodic Status
1. Feature pages should be updated to reflect the current status of the feature by the following milestones on the Release Engineering schedule:
- Alpha freeze
- Beta freeze
- For features not 100% complete--every two weeks after 'beta freeze until final development freeze
1. At final development freeze all feature pages should be at 100% completion, and if necessary, the feature page adjusted to reflect everything completed (so as to reflect 100% completion). 1. Feature Wrangler will send individual reminders and announcements to fedora-devel-announce list as necessary 1. A summary status for all the features targeted to a particular release will be collected on a summary page which references and briefly explains the feature.
- The Feature Wrangler will maintain this page.
- This page will be located at: http://fedoraproject.org/wiki/Releases/<release number>/FeatureList
1. Reminders to developers about upcoming feature deadlines will be sent to email@example.com 1. Nag mail to developers with delinquent feature page updates will be emailed privately and shamed in a nice way on firstname.lastname@example.com
Important Milestones
- New features may be proposed (using the guidelines above) and accepted no later than the feature freeze milestone
- New features must be feature complete or close enough to completion that a majority of its functionality can be suitably tested--the "feature is testable".
- At feature freeze the Feature Wrangler will present a final feature status to FESCo which FESCo will review and comment on
- After final review by FESCo at Feature Freeze the final accepted Feature list (Release Road Map) will be publicly announced by the Feature Wrangler.
Dropping Features
A feature will be proposed for a vote to be dropped from the Accepted Feature list by FESCo if one of the following occurs:
- Feature is incomplete or not testable at Feature Freeze
- Feature owner fails to consistently provide status or attend IRC meetings (if held).
Partially completed features can still be listed as accepted for the upcoming release if the wiki page describing the feature is tailored to reflect the completed work. Dropped features can be proposed again for inclusion in the next release.
Exception Process
- Features not meeting the guidelines above may be brought to a FESCo meeting for review.
A person responsible for managing features, a Feature Manager, is designated by the Fedora board and reports to FESCo as outlined here: https://www.redhat.com/archives/fedora-advisory-board/2007-June/msg00022.html
The Feature Manager is commonly known as the Feature Wrangler.
The Feature process was created because in previous releases of Fedora, the status and handling of new features was not completely defined. This resulted in last minute surprises when a particular feature that had been advertised as being an important part of the next release was not ready or its status was unclear. The Fedora Board wants Fedora releases to have a predictable release schedule. Proactively monitoring features on a periodic basis should help to add predictability to the release schedule and clearly communicate which new features should be expected in the next release of Fedora.
If everyone working on the next release of Fedora acts independently without communication or coordination between themselves we end up with simply a pile of bits at the end. The value of having features defined up front is many-fold:
1. Everyone has an idea of what everyone else is working on. This provides the opportunity for feedback and suggestions for improvement. 1. You get people interested--perhaps even helping out 1. You get some idea of areas that are going to need testing so that testers can build up experience and knowledge about the area 1. You generate excitement around what's being worked on 1. You avoid surprises at the end 1. Public accountability to do what we say we are going to do 1. Easier Release Notes creation for new features--everything needed is on the individual feature pages. 1. Ability to list out a set of features to be picked up or when talking to the media/press. Fedora ambassadors and any promotional efforts would find a feature list useful.
All of these are important. And yes, some things that are planned will not make it. That is fine. By tracking them, we should be able to know sooner that a feature is in trouble so that others can either jump in to help out or to begin setting expectations that it will not happen.


text:
Nanomedicine Fact Sheet
Nanomedicine Overview
What if doctors had tiny tools that could search out and destroy the very first cancer cells of a tumor developing in the body? What if a cell's broken part could be removed and replaced with a functioning miniature biological machine? Or what if molecule-sized pumps could be implanted in sick people to deliver life-saving medicines precisely where they are needed? These scenarios may sound unbelievable, but they are the ultimate goals of nanomedicine, a cutting-edge area of biomedical research that seeks to use nanotechnology tools to improve human health.
Top of page
A lot of things are small in today's high-tech world of biomedical tools and therapies. But when it comes to nanomedicine, researchers are talking very, very small. A nanometer is one-billionth of a meter, too small even to be seen with a conventional lab microscope.
Top of page
Nanotechnology is the broad scientific field that encompasses nanomedicine. It involves the creation and use of materials and devices at the level of molecules and atoms, which are the parts of matter that combine to make molecules. Non-medical applications of nanotechnology now under development include tiny semiconductor chips made out of strings of single molecules and miniature computers made out of DNA, the material of our genes. Federally supported research in this area, conducted under the rubric of the National Nanotechnology Initiative, is ongoing with coordinated support from several agencies.
Top of page
For hundreds of years, microscopes have offered scientists a window inside cells. Researchers have used ever more powerful visualization tools to extensively categorize the parts and sub-parts of cells in vivid detail. Yet, what scientists have not been able to do is to exhaustively inventory cells, cell parts, and molecules within cell parts to answer questions such as, "How many?" "How big?" and "How fast?" Obtaining thorough, reliable measures of quantity is the vital first step of nanomedicine.
As part of the National Institutes of Health (NIH) Common Fund [nihroadmap.nih.gov], the NIH [nih.gov] has established a handful of nanomedicine centers. These centers are staffed by a highly interdisciplinary scientific crew, including biologists, physicians, mathematicians, engineers and computer scientists. Research conducted over the first few years was spent gathering extensive information about how molecular machines are built.
Once researchers had catalogued the interactions between and within molecules, they turned toward using that information to manipulate those molecular machines to treat specific diseases. For example, one center is trying to return at least limited vision to people who have lost their sight. Others are trying to develop treatments for severe neurological disorders, cancer, and a serious blood disorder.
The availability of innovative, body-friendly nanotools that depend on precise knowledge of how the body's molecular machines work, will help scientists figure out how to build synthetic biological and biochemical devices that can help the cells in our bodies work the way they were meant to, returning the body to a healthier state.
Top of page
Last Updated: January 22, 2014
Here is the original post:
Nanomedicine Fact Sheet


text:
The textbook industry will never be the same. Apple has just made it easy for educators to create and publish their own textbooks with the new app iBooks Author. According to MacWorld, the app is as easy to use and works seamlessly with other apple products like Pages and Keynote.
What does this mean for teachers and school districts? This will enable us to create highly customized materials at significantly less cost than previously possible. The textbook publishers no longer hold the reins on the quality of content delivered to students.
It will also allow for dynamic, interactive ebooks that incorporate video, sounds, links and high quality images. As with all ebooks, students will have the benefits of keyword searches, highlighting, annotating and bookmarking. As well as having all their books and notes stored in one lightweight device!
Also announced today is the new iTunes U app which allows teachers to create an entire course curriculum with video, documents, apps and books. Students can search iTunes U catalog to browse ratings, description and course outline. iTunes U is already being used by colleges and universities. Now, for the first time, it is available for K-12 schools.
The new iBooks 2 app, iBooks Author and iTunes U app are all free. Although, it is too early to tell how these products will affect classroom instruction, providing access to tools that steer the K-12 system away from traditional methods of content and instruction delivery is another step in the right direction.


text:
Words that embody people or things in your periphery are "Air, Anonymity, Attention, Bank, Cabal, Chocolate, Circus, Compliance, Copper, Crimson, Crown, Darkness, Dictionary, Drama, Emissary, Excitement, Exhaustion, Future, Gangster, Genetics, Groove, Harbinger, Hell, Hermit, Hunger, Invader, Labyrinth, Lamb, Liberty, Man, Merchant, Mirror, Nation, Need, Number, Numerology, Obelisk, Octopus, Overlord, Panther, Parliament, Phoenix, Portal, Prison, Psychedelic, Psychology, Pulse, Quest, Rainbow, Sacrifice, Satisfaction, Scorpion, Sensuality, Soldier, Sound, Sparkle, Spirit, Stone, Struggle, Succubus, Supply, Suspense, Syzygy, Tattoo, Theory, Throat, Tongue, Usurper, Utopia, Warlord, Zenith".
Words that embody the people or things that you interact with are "Charity, Commune, Cosmos, Daughter, Fervor, Lantern, Martini, Pluto, Spectacle, Vampire".
Words that embody things that you may be a part of are "Destruction".
Words that embody people or things in your periphery are "Transformation".
Words that embody the causes of your circumstances are "Cabal".
Identity: These are words whose numeric value is an exact match. For example, the numeric value of "Adolf Hitler" is 110, which is the same numeric value as "Osama Bin Laden" (as bad luck would have it, Adolf and Osama share the same Tarot card and birth path as well). Identities are common in some fundamental way, although the commonality may be very obscure. You might think of words as the siblings of their identities.
Product: These are words whose numeric value is a superset of another. For example, the numeric value of "Fulfillment" is 130, which is a superset of the numeric value of "Peace", which is 30. Products are things that you can create from their components.
Component: These are words whose numeric value is a subset of another. For example, the numeric value of "Sex" is 48, which is a subset of the numeric value of "Sharon Stone", which is 148. Components are things that make up a product.
Mirror: These are words whose numeric value is a digit by digit reflection. For example, the numeric value of "Rose" is 57, whereas the numeric value of "Thorn" is 75. Mirrors are things that belong together, either as compliments or as opposites. Like a thorn to a rose, mirrors are often unrelated in what they offer, but inextricably connected nonetheless. Words are sometimes thought of as the allies or enemies of their mirrors.
Cause: These are words whose value matches the secondary numeric value of another. For example, the date "9-11-2001" has a numeric value of 14 (9+1+1+2+0+0+1=14), the word "Warning" has a numeric value of 86, and the word "Martyr" has a numeric value of 95. If you add up the digits of "Warning" (8+6=14) and "Martyr" (9+5=14), the results equal the value of "9-11-2001". Causes are things that precede their effects.
Effect: These are words whose secondary numeric value matches the value of another. For example, the numeric value of "Winter" is 89, and the numeric value of "Ice" is 17. If you add up the digits of "Winter" (8+9=17), the result equals the value of "Ice" (17). Effects are things that follow their cause.
Distant: These are words whose secondary numeric values are an exact match. For example, the numeric value of "Rome" is 51, "War" is 42, and "Conquest" is 114. If you add up the digits (5+1=6, 4+2=6, 1+1+4=6), each one equals 6. Distants are things that are loosely related, like cousins within a family.
Italics: The words in your reading that appear in italics are more strongly associated with you than the other words in the same category. For example, if your reading included the line "Distant: trance, struggle, victory", then all three of these words would be loosely related to you, but the word struggle would be the most significant among them.


text:
An update to my Thunderbird TNEF script for opening winmail.dat
Back in July I blogged about Opening winmail.dat (TNEF) files in Thunderbird (on Ubuntu). Well a colleague at work has 'refined' my script so that rather than it create a folder on your desktop it simply opens Nautilus to display the contents of the attachment.
This is the new version of the script:
#!/bin/bashThe interesting part of this script for me is the
mkdir $LOCATION
/usr/bin/tnef -C $LOCATION --save-body -f $1
nautilus $LOCATION
$$ - this special script variable is the process ID (PID) of the currently running script, so it makes a temporary file called
winmail_<current process id>.dat. Other than that it's pretty similar to my original script apart from opening Nautilus at the end.
Now it's even easier to open and extract files from winmail.dat files!
I found out the reason for the
$$ from here.
Technorati Tags: winmail.dat, TNEF, Thunderbird, Ubuntu, Andrew Beacock


text:
You'll see: "Wicked" rips the lid off of Oz.
Rips it right off.
Dirty politics.
Domestic surveillance.
A love child.
Racial discrimination (y'know, against the green-skinned coloreds).
Emotional abuse.
Animal rights.
And then, in the second act, there's torture, terrorism, media manipulation, Munchkin oppression and a witch-hunt.
A REAL witch-hunt.
But when "Wicked" lands in Fort Lauderdale March 30-April 24, it will look just like a great big ol' satisfying Broadway musical comedy with all the requisite physical humor, eye-popping production numbers as well as jaw-dropping costumes mixed with witty lyrics and soaring music by Stephen Schwartz.
But as goofily funny as "Wicked" can be, there just no getting around it: Oz is now topical as all ... um ... heck.
"Those are plot points, but they are not the driving themes of the show," said producer David Stone from his Manhattan offices. "It's about empowerment. It's about media and spin. And what's history. Who writes the history? And who decides what is good and what is wicked?"
Stone is also the theatrical producer behind the Great White Way hits "Next to Normal" and "The 25th Annual Putnam Spelling Bee."
"I also think it's about friendship. A deep, real friendship — the kind only women really have. It's really about those two little girls."
It is now. But "Wicked" is based on a 1995 novel by Gregory Maguire, who has jettisoned to fame and fortune with his revisionist works that, for example, sample from "Cinderella" ("Confessions of an Ugly Stepsister" in 1999) and "Snow White" ("Mirror, Mirror" in 2003).
Remixed and rebooted from "The Wizard of Oz," Maguire set the story of his "Wicked: The Life and Times of the Wicked Witch of the West" in the Land of Oz years before Dorothy Gale plops down in Munchkin Land. The retelling of L. Frank Baum's "The Wizard of Oz" a la Maguire is much darker and threatening, too dark and threatening by far for a family-friendly musical.
The [Broadway show] is the story played in a different key," Maguire said. "There are some chamber pieces from composers ... Tchaikovsky, for example, who put some things in a lower register with these atonal chords. Broadway sort of moved the register [of "Wicked"] up to the key of bittersweet. It is not the key of tragedy ... and that is appropriate."
Maguire doesn't think he's the source of the story's ripped-from-the-headlines feel. Look to Baum's original work instead he insists.
"When I read the [L. Frank Baum] book, I found it absolutely chilling. Dorothy goes off to kill the Wicked Witch of the West because she has been told that she deserves to die. Dorothy is a paid political assassin. The Wicked Witch never gets to speak for herself. She never gets to sing. So I decided she was going to sing in my novel."
Maguire says that Elphaba singing is one of the things he enjoys most about the transfer of his book to the stage, a feat that originally garnered mixed reviews for Schwartz, Joe Mantello (director) and Winnie Holzman (book).
"I knew Elphaba could sing even before Broadway got ahold of her," said Maguire from the Massachusetts home he shares with painter Andy Newman and their three adopted children. "In the original movie, the way they make her so scary is by keeping her offstage, as it were. She's only on for about 12 ½ minutes. But she totally dominates the movie. Too much actually; they had to cut her scenes down."
The musical made a lot of changes moving the story from one medium to another. But Maguire adds that the headlines of recent history have also shifted ever so slightly the way he thinks his novel is being read today.
"I thought I was writing a book with an old-fashioned aspect to it with some social ills that we had more or less matured beyond," Maguire said.
"I was thinking Pinochet in Chile; Nazi Germany; Ceausescu in Romania. I thought, 'contemporary readers will read this.' Then I found we hadn't some sort of sepia-toned memory at all. 9-11 happened and, of course, the fear mongering that followed. And I think it changed how people read it. I realized that now this was a story about being cautious about how convinced you are about your own rightness."
Whatever the take-away is, the Broadway juggernaut is wrapped up in a Crayola-colored glossy package like a Broadway hit should be. "Wicked" still casts a spectacular, yet sly, spell. Stone's favorite audience reaction story bears that out:
"I heard this one mom and her — I guess she must have been about 10 years old — daughter and they were coming out of the theater and the mom said, 'You know it's about not judging people.' And the daughter said, 'I know mom, it's a metaphor.' "
If You Go
The musical "Wicked" reopens March 30 and runs through April 24 at Broward Center Au-Rene Theater, 201 SW Fifth Ave., Fort Lauderdale. Shows 8 p.m. Tuesday-Saturday; 7:30 Sunday; 2 p.m. Saturday, Sunday and March 31, April 21. Tickets $36-$168.60, browardcenter.org, 954-462-0222 or Ticketmaster.com, 800-745-3000.


text:
Hi, I'm Eric Lawrence from the Internet Explorer Security Team. With the RSA security conference kicking off this week, I wanted to start sharing more information about the security features and benefits of Internet Explorer 8 Beta 1. Over the next several weeks, we'll blog in greater detail about some of the security improvements in Beta 1, such as the new Safety Filter, greater control over ActiveX controls, and new AJAX features for safer mashups (XDomainRequest and XDM). This is not a complete list of our security investments for the release; we will have more to talk about during future milestones.
Internet Explorer 8 security features target three major sources of security exploits: social engineering, Web server, and browser-based vulnerabilities. This post will cover IE8 Data Execution Prevention (DEP), a feature that mitigates browser-based vulnerabilities.
DEP/NX Memory Protection in Internet Explorer 8
Internet Explorer 7 on Windows Vista introduced an off-by-default Internet Control Panel option to "Enable memory protection to help mitigate online attacks." This option is also referred to as Data Execution Prevention (DEP) or No-Execute (NX).
We have enabled this option by default for Internet Explorer 8 on Windows Server 2008, Windows Vista SP1 and later, and Windows XP SP3 and later.
DEP/NX helps to foil attacks by preventing code from running in memory that is marked non-executable. DEP/NX, combined with other technologies like Address Space Layout Randomization (ASLR), make it harder for attackers to exploit certain types of memory-related vulnerabilities like buffer overruns. Best of all, the protection applies to both Internet Explorer and the add-ons it loads. No additional user interaction is required to provide this protection, and no new prompts are introduced.
DEP/NX Compatibility
For Internet Explorer 7, DEP/NX was disabled by default for compatibility reasons. Several popular add-ons were not compatible with DEP/NX and would crash when Internet Explorer loaded them with DEP/NX enabled. The most common problem was that these add-ons were built using an older version of the ATL library. Before version 7.1 SP1, ATL relied upon dynamically generated code in a way not compatible with DEP/NX. While developers of many popular add-ons have since released updated extensions compatible with DEP/NX, some add-ons may not be updated before Internet Explorer 8 becomes available.
Fortunately, new DEP/NX APIs have been added to Windows Server 2008 and recent Windows Service Packs to enable use of DEP/NX while retaining compatibility with older ATL versions. These new APIs allow Internet Explorer to opt-in to DEP/NX without causing add-ons built with older versions of ATL to crash.
In rare cases where an add-on is not DEP/NX compatible for reasons other than outdated ATL usage, a group policy option will be available to allow an organization to opt-out of DEP/NX for Internet Explorer until an updated version of the broken add-on can be deployed. Local Administrators can control DEP/NX by running Internet Explorer as an Administrator and unchecking the Tools > Internet Options > Advanced > "Enable memory protection to help mitigate online attacks" option.
Checking Your Protection
You can see which processes are protected by DEP/NX on Windows Vista Task Manager's Process tab; on earlier versions of Windows, you can use Process Explorer. In either case, ensure that the "Data Execution Prevention box" is checked in the View > Select Columns menu.
Developer Call to Action
If you build Internet Explorer add-ons, you can help ensure users enjoy a smooth upgrade to IE8 by taking the following steps today:
- If your code depends on older versions of ATL, please rebuild it with ATL v7.1 SP1 or later (Visual Studio 2005 includes ATL 8.0)
- Set the /NXCompat linker option to indicate that your extension is compatible with DEP/NX
- Test your code with DEP/NX enabled using IE8 Beta 1 on Windows Vista SP1. (Alternatively, test with IE7 on Windows Vista after enabling the DEP/NX option. To enable DEP/NX for IE7: Run IE as an administrator, then set the appropriate checkbox in the Tools > Internet Options > Advanced tab)
- Opt your code into other available defenses like stack defense (/GS), safe exception handling (/SafeSEH), and ASLR (/DynamicBase)
Thanks for your help in securing the web!
Eric Lawrence
Program Manager
Updated 9/14/2009 to reflect that DEP/NX protection is enabled on Windows XP SP3. While Windows XP does not offer ASLR protection, DEP/NX alone does make exploitation somewhat more challenging.
Update: Are you encountering DEP/NX crashes in Internet Explorer 8? See this post for more information.


text:
Browse by Medical Category
Research at Mass General
Group Members
FellowsToshimi Yoshida, PhD, Instructor in DermatologyTaku Naito, PhD, Instructor in DermatologyJohn Seavitt, PhD, Research FellowMariko Kashiwagi, PhD, Research FellowIdit Hazan, PhD, Research FellowIla Joshi, PhD, Research Fellow StudentSamuel Ng, Graduate Student, Program in Immunology HMS Research AssistantRobert Czyzewski CollaboratorsJiangwen Zhang, PhD, Senior Computational Biologist FAS Center for Systems Biology, Harvard UniversityBruce Morgan, PhD, Associate Professor of Dermatology, CBRC
Research Projects
In many developmental systems, nuclear regulators have been implicated in coupling key events in gene expression with specific cell fate and lineage decisions. Focusing on this topic in the hemo-lymphoid system, we have identified the Ikaros gene family of zinc finger DNA binding proteins and shown in a series of genetic studies that they function as key regulators of lymphocyte specification working from the level of the hemopoietic stem cell (HSC). These fundamental studies continue to contribute insight into the earliest steps of the B and T cell differentiation pathways and the molecular network that supports cell fate decisions in the hemo-lymphoid system.
The molecular mechanisms by which Ikaros and its family members exert their range of effects in the hemo-lymphoid system have been under investigation using molecular and biochemical approaches. Importantly, purification of Ikaros and its family member Aiolos from both resting and activated lymphocytes has shown that they exist as part of two functionally distinct chromatin remodeling machineries; an Ikaros-NURD complex, which contains the DNA-dependent ATPase Mi-2 and histone deacetylases, and an Ikaros-SWI/SNF complex which contains the DNA-dependent ATPase Brg-1. Essentially all of the Ikaros found in lymphocytes is in these two higher order molecular entities. This provides an unprecedented example of a factor with demonstrated function as an essential regulator of mammalian development that acts possibly by guiding functionally distinct chromatin remodeling machineries. This combination of attributes makes Ikaros an ideal entry point to study epigenetics in stem cell commitment and differentiation. Our current work focuses on the ability of Ikaros proteins to partition in these functionally distinct higher order molecular complexes and the way that these distinct complexes alter chromatin structure and expression of lineage-specific genes. The genetic interactions between Ikaros and its chromatin remodeling associates are being explored in a series of conditional inactivation studies in mice. These studies are providing evidence of a regulatory network that is comprised of positive and negative regulatory factors whose intimate interactions are responsible for developmental decisions and homeostasis in the hemopoietic system.
Studies on Ikaros gene regulation continue to target our original goal of determining the combination of transcriptional inputs required for induction of a HSC gene expression program. Ikaros regulatory elements coupled with genes encoding fluorescent markers are proving invaluable for the effective separation of rare stem cell and precursor activities and are allowing an in vivo real time analysis of their development. Achieving these goals will dramatically increase the ability to analyze and manipulate development of the HSC in vitro with potential therapeutic implications.Areas of research:1. Ontogeny of the hemo-lymphoid system.Critical insight into the regulation of the early steps of the hemo-lymphoid pathways was obtained by studying mice with Ikaros mutations. Ikaros expressed in the HSC is required for the production and maintenance but also the differentiation of HSC into the lymphoid pathways. Studies on the hemo-lymphoid hierarchy in the Ikaros mutant mice have identified gene targets responsible for some of the cellular defects and have generated a platform on which to study the molecular mechanisms employed by these factors. Studies on Ikaros regulatory elements, which are active in the HSC and progenitor compartments, are also providing us with powerful molecular tools to study transcriptional regulation at the very first steps in the hemopoietic pathway. These Ikaros regulation studies have increased our ability to manipulate gene expression in the early hemo-lymphoid populations and further dissect the HSC compartment and lymphoid progenitors and precursors. (Select publications: 1, 2, 8, 10)2. Immune response/lymphocyte function.Studies on the mature T and B cell populations in mice with deficits in Ikaros, Aiolos and more recently in their associate Mi-2 have identified a nuclear network that controls a lymphocyte's response to stimulation and its subsequent maturation to an effector state. Studies on Aiolos deficient mice in particular have provided us with some of the mechanisms that control the fate of naive mature B cell upon antigenic encounter. Importantly, the decision of a naive B cell to assume a marginal zone or a follicular B cell fate, a B cell's ability to enter a Germinal Center (GC) reaction, as well as selection of GC B cells for high antigen specificity are all processes that are dependent on Aiolos. Furthermore, the high affinity long-lived plasma cell population that resides in the bone marrow and is responsible for long-term humoral immunity but not other plasma cells requires Aiolos for its generation. (Select publications: 5, 6, 12, 13)3. Lymphoid cancers.Proliferative responses in T and B cells depend on levels of the DNA binding isoforms of Ikaros and Aiolos or their activity. Progressive reduction in Ikaros and Aiolos DNA binding factors in respective T and B cell populations results in a progressive increase in proliferative responses and cause rapid neoplastic transformations. (Select publications 3, 5, 6, 12)4. Chromatin regulation of hemo-lymphopoiesis.The Ikaros family proteins represent an important group of developmental regulators. Their association with chromatin remodeling machineries (NURD and SWI/SNF) has provided evidence for a critical role of chromatin regulation in lineage-specification. Studies on the CD8 gene have provided us insight on how Ikaros promotes accessibility at the CD8 enhancers and allows for activation of these enhancers during T cell development. The wealth of markers for lineage progression, and the ability to analyze this process in mouse mutants and in vitro, make the hemo-lymphoid system an ideal model to study the role of directed chromatin remodeling in lineage progression. The Ikaros family and its associates are uniquely suited representatives for these studies. The insights gained by studying Ikaros and its associates, their gene targets and effects on chromatin structure serve as a paradigm for research in this field. They also provide us with the ability to study how hemopoiesis and the immune response are regulated at this molecular level. (Select publications: 7, 9 and 13)
5. Development of complex epithelia.Development, morphogenesis and self-renewal of skin appendages share some intriguing parallels to hemopoiesis. The accessibility, and self-renewal features, coupled with its highly organized and fascinating architecture, make the skin an attractive system for exploring the molecular mechanisms that underlie stem cell properties as well as complex differentiation programs. The Ikaros homologues Helios and Dedalos and their associated chromatin remodelers are highly expressed in the developing epithelia of the skin. We are now utilizing epithelial-specific conditional inactivation and biochemical approaches to address the role of these factors during skin development and morphogenesis. We hope that our past expertise on the hemopoietic system combined with the local expertise on skin differentiation will in the near future provide a breakthrough in the mechanisms that control epithelial development.
Transgenic and Gene Targeting Facility
nt breakthroughs in lineage transcriptional priming
Table.1 Lineage-specific signatures deduced by K-mean clustering (Ng. et. al., Immunity 2009; 30: 1-15)
View my publications at PubMed
Science. 1992 Oct 30;258(5083):808-12.PMID: 1439790
Back to Top


text:
We believe the best inspire the best. At JLL, we attract the best people – and we focus on supporting each other, learning together and celebrating our success. Wherever your role takes you, you're among likeminded people who work naturally together to achieve great things. Things we can all be proud of.
With an entrepreneurial spirit and open mind, we make the most of every opportunity – in our careers, for our clients and for our business, around the world.
We develop world-class teams where talented people learn from and inspire each other. Our success is underpinned by the diverse backgrounds, skills and ideas that we value and embrace.
Join us to develop your strengths and enjoy a fulfilling career full of varied experiences. Keep those ambitions in your sights, and imagine where JLL can take you
Learn More


text:
So, a few years ago my friend Min taught me to make this mochi-esque dessert/snack/treat: Mix sweet/sticky/glutinous rice flour with enough water to make a batter with the consistency of heavy cream. Pour that onto a buttered flat plate or flat form so that you have a nice large 1/8" or 1/4" flat pool of batter. Microwave or steam (microwaving is vastly faster for me) for a minute or two, watching carefully. The batter is cooked when it has changed from bright opaque white to a more translucent white/pearly grey. Heat a tablespoon or so of red bean paste for 10 seconds (in the micro) or so, just to soften it, and spread carefully on the mochi. Roll up, and then slice into 3/4" or so pieces. Roll each of these around in a little bowl of unsweetened coconut flakes (toasted their even nicer). So, this is super yummy.
Recently I learned about a more Japanese-style mochi where you combine a generous half cup of the sweet/sticky/glutinous rice flour with *just* enough water to make a very stiff dough. It feels like a sort of silky playdoh when it's right, and I've found that it's easy to add too much water. I've fixed this by adding just a little water at a time, and really mixing it well with a fork. It starts out all crumbly, and with just a few more drops water begins to cohere properly.
Bring a pot of water to a boil.
Take a generous tablespoon's worth of dough and roll into a sphere, like a large marble. Repeat with the rest of the dough. I generally make 6 or 8 mochi with the above amount of flour. Using a spoon, drop each ball into the boiling water, and boil until the balls have risen to the surface, plus 2 or 3 minutes. Use a spider or a spoon to lift each mochi ball into a bowl.
I like them with these toppings:
A sweetened soy sauce: 2 T soy sauce with 1 t of sugar --both savory and sweet and delicious
A mix of 1 T soy flour with 1 T raw or muscovado sugar (or regular sugar)
Another fun thing to do is to take each ball (before boiling) and flatten in your hand. Make a little depression in the disk of dough and put a little ball of sweet red bean paste there. Just a tiny bit, like maybe the size of a pea. Carefully fold up the disk of dough to seal in the bean paste, and then roll the ball carefully. Boil like above. When I make these, I like making a little dimple in the ball with my finger. They come out very adorable with a little innie-bellybutton like spot, and then with a drizzle of maple syrup, just a tiny bit, oh my these are good.
Another fun thing I did: I mixed a few drops of some beet water (water I saved from boiling up a mess of beets the other day) and made pink mochi. The colour was super cute, and there was no earthy odd beet flavor at all, just the pretty colour.
I understand that there is a `dark syrup' that is traditional with Japanese mochi, and I'd love to learn to make that. Any ideas? In fact, any mochi tips, tricks, lore, topping ideas, etc. would be lovely.
This is not exactly diet food, but it's the food I have a hot crush on right now. And in fact, I reckon in small portions as part of a diet otherwise low in sweets, well, it's not the worst thing in the world.
Wow...That sounds great. I think that I need to make a trip to Japan town soon for some mochi and other treats.
You may want to browser the wagashi category on Just Hungry. The syrup you mention is probably 'kuromitsu', and is basically molasses or (in the UK) black treacle. I've used it for kuzumochi. Once I settle into a new kitchen (not to mention house) I'd like to work on more wagashi recipes!
The Big Onigiri.
- Wherever you go, there you are. -
Wow! I love that wagashi series of posts; thank you. I have been hot on the trail of the ichigo daifuku holy grail for a few days now. I've never tasted one, but I love all three components, and I'm fascinated and drawn to the ardor with which my Japanese friends regard this sweet. I know how deep-seated my own cultural food passions are (rød grød med flød på, mmm), and so a treat like ichigo daifuku seems fantastically appealing. And kismet led me past a basket of incredible strawberries the other day, and so tomorrow is the big ichigo daifuku making day, I think :-)
I'm also going to make a trio of dango called botchan dango, maybe tonight if I perk up a bit.* One dough is flavored/coloured with matcha, the second dough with egg yolk, and the third with red bean paste, and each one has a center of shiro an (white bean paste).
I particularly like that no-nonsense post about how wagashi is not Magic Japanese Diet Food; I just adore the dry, bracing, down-to-earth tone of that and similar writing you do.
*I fell asleep mid post, so I think the botchan will wait 'til another day ;-)
|Last Post
|Sesame salad dressing
|5 years 40 weeks ago
|Authentic paella?
|5 years 42 weeks ago
|IMPORTANT: If you have a blog on JustBento...
|5 years 44 weeks ago
|Shiso - uses for this herb
|5 years 46 weeks ago
|Fuki (Japanese Butterbur) Tsukemono Recipes
|5 years 46 weeks ago
@justbento - strictly site updates
@makiwi - Maki tweets at random


text:
Measure buildings, fields, lakes or your own windows by importing images from Google Maps directly in Image Measurement.
Download Order now
Measure length, area, angle and circumference on images with Image Measurement
If you need to follow the development of your measurements over time Image Measurement is ideal and easy to work with.
Make it easy for yourself and use Image Measurement to generate your reports
Image Measurement supports a wide array of file formats - besides the common ones, files such as DICOM, layers, vectorial objects, as well as proprietary formats of Photoshop and Camera RAW are widely accepted.
Record a video or take a picture of an event with Image Measurement by plugging in your (video)camera and measure on the chosen video frame or picture.
Thank you for contacting us! We will get back to you soon.
Order now
Download free trial


text:
Starcasm: Worst red carpet pose ever? Konnie Huq at Harry Potter and the Deathly Hallows Premiere
Hispanic Business: Lynda Carter to Megan Fox: Shut Up
Socialite Life: Mischa Barton's Extensions Cause Stank Face
AP: The eyes have it: Woman chased, bitten by raccoon
HuffPo: The Funniest Auto Correct Fails (PHOTOS) (thanks jash. This made me cry)
LA Now: Australian businessman arrested in fatal Sunset Strip crash involving Bentley; Detectives say alcohol may be factor
ABC 7: Calif. AG sues maker of 'Brazilian Blowout'
Bottle Service is for Tourists: The Alliance
LA Weekly: A Movable Beast: L.A. Weekly's 99 Essential Restaurants
The Dartmouth: Blitz Lives
gas•tron•o•moy: Kam Hong Garden – Monterey Park
Movieline: Survivor: Ranking Nicaragua's Top 10 Finalists
AND WHATNOT: Worst Red Carpet Pose Ever; Also, Auto-Correct Mishaps, 'Survivor,' and LA's 99 Essential Restaurants
Starcasm: Worst red carpet pose ever? Konnie Huq at Harry Potter and the Deathly Hallows Premiere


text:
Buchholz and Bowden
Clay Buchholz made his third start of the season on Monday night at Lehigh Valley and reminded everyone in attendance that there isn't a pitcher in minor league baseball with better stuff.
His fastball hit 97 on the stadium radar gun, and he was getting numerous swings and misses on all four of his pitches (fastball, curve, slider, and changeup). In six innings, Clay allowed three hits, walked one, and struck out seven (six swinging and one looking on a nasty curve).
Unfortunately, he made one mistake — a 2-0 fastball that John Mayberry Jr. hit out of the yard to tie the game at one in the 5th inning, and the IronPigs eventually beat the PawSox 2-1 in 12 innings.
Still, it was a treat to watch. Clay's next start will be at McCoy Stadium on Sunday if you would like to see for yourself.
(Although be prepared to stay awhile. All three of Clay's starts have gone to extra innings this year).
* * * * *
Quite a weekend for Michael Bowden huh?
On Saturday night around midnight, manager Ron Johnson called Bowden on his cell phone to tell him he needed to be on a plane in a few hours to report to Fenway Park for Sunday night's game against the Yankees.
"I was already under the covers in bed, flipping through the channels, and I actually missed RJ's call," Bowden told me. "I usually don't listen to my voicemails right away, but for some reason I decided to listen to that one and it was RJ telling me to call him right back. When I called him he told me I was going to Boston, but there was a pretty good chance I wouldn't get to pitch – it was an emergency-type thing. At 1 o'clock in the morning they brought me my stuff from the clubhouse, and at 9:30 I was on an airplane ready to go."
Bowden was the first player to arrive in the Red Sox clubhouse that afternoon and said his teammates were surprised to see him. Shortly after that, he got a surprise from Terry Francona.
"I went into his office to say hi and thank him for the opportunity and he said there was a 95 % chance I would pitch that night in relief," Bowden said with a laugh.
Red Sox fans know how it turned out. The 22-year-old righty tossed two scoreless innings against the Yankees to help Boston complete a 3-game sweep and a perfect 9-0 homestand.
"It was one of the most bone-chilling things I've ever experienced," Bowden said. "I said after my major league debut that it was a dream come true, but experiencing that atmosphere against the New York Yankees. . .close game. . .packed house. . .Sunday night on ESPN. . .it was just an unbelievable experience. I can't even describe it."
Immediately after the game he was optioned right back to Pawtucket. The same thing happened last August after Bowden beat the White Sox in his major league debut.
"We were joking around in the clubhouse today that I have 11 hours of major league service time and I have a win and a hold," Bowden said. "Both of my trips have been quick, but I'll take it."
He'll be back. Eventually for good.
* * * * *
After a sizzling start, Hyder has dropped to 7-7 in "Stump Steve."
On Monday in honor of Clay Buchholz — the only rookie in Red Sox history to throw a no-hitter — we played "2 Out of 3 Ain't Bad" about MLB rookies who have thrown no-hitters.
1. I threw a no-hitter as a rookie in 1970, and won the Cy Young Award and MVP award the following year.
2. In my major league debut in 1991, I walked two batters, allowed a single, and gave up 2 home runs without retiring a batter for an ERA of infinity. In my next start, I tossed a no-hitter.
3. I threw a no-hitter as a rookie in 1967 and threw another no-hitter in 1969 making me a member of two exclusive clubs — rookie pitchers who threw no-hitters and pitchers who threw more than one.
The answers are:
1. Vida Blue (Hyder incorrectly guessed Steve Carlton).
2. Wilson Alvarez (Steve got it right).
3. Don Wilson (Hydes incorrectly guessed Jim Palmer).
We'll see if he can get back on the winning track on Tuesday night at Syracuse. I hope you'll tune in for the broadcast beginning with the pregame show at 5:45 on the PawSox radio network and PawSox.com.
I'd love to hear from you. The address is email@example.com.


text:
The Internship Program assists students with locating paid career and volunteer positions with corporations, businesses, nonprofit agencies and institutions. For more information, contact the Internship Program Office at (562) 985-8463 or http://careers.csulb.edu/job_search/internships/index.htm, or go to Brotman Hall, Room 250.
Listings are available and assistance is offered in the Career Development Center to students interested in part‑time employment. On-campus Federal work-study and off-campus positions are available. Students can access these listings on BeachLink, CSULB's online job posting board at http://careers.csulb.edu.
Many CSULB departments have Teaching Associate (TA) and/or Graduate Assistant (GA) positions available for qualified graduate students. Students should check in department offices or on the campus web site for more information.


text:
A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
|ClinicalTrials.gov Identifier: NCT01782313
Recruitment Status : Completed
First Posted : February 1, 2013
Results First Posted : August 21, 2018
Last Update Posted : September 18, 2018
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
|Condition or disease
|Recurrent Adult Soft Tissue Sarcoma Stage III Adult Soft Tissue Sarcoma Stage IV Adult Soft Tissue Sarcoma
|Drug: tivozanib Other: laboratory biomarker analysis
|Phase 2
I. To determine the progression-free survival (defined as complete response [CR] + partial response [PR] + stable disease [SD]) assessed at 16 weeks for patients treated with tivozanib.
I. Overall response rate (defined as CR + PR). II. Clinical benefit rate (CR + PR + SD). III. Overall survival (up to 2 years beyond progression). IV. Correlation of clinical outcome with antibodies for vascular endothelial growth factor receptor 1 (VEGFR1) and VEGFR2.
V. Assess Safety and tolerability.
Patients receive tivozanib orally (PO) daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity, or until discontinuation per patient preference or physician recommendation.
After completion of study treatment, patients are followed up every 3 months for 2 years.
|Study Type :
|Interventional (Clinical Trial)
|Actual Enrollment :
|58 participants
|Intervention Model:
|Single Group Assignment
|None (Open Label)
|Primary Purpose:
|Official Title:
|A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas
|Actual Study Start Date :
|March 6, 2013
|Actual Primary Completion Date :
|July 27, 2015
|Actual Study Completion Date :
|December 28, 2016
Experimental: Treatment (tivozanib)
Patients receive tivozanib PO daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Drug: tivozanib
Given PO
Other Names:
Other: laboratory biomarker analysis
Correlative studies
- Percentage of Patients With Progression-free Survival at 16 Weeks. [ Time Frame: At 16 weeks of treatment. ]
Progression-free survival from study disease will be evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) Committee, version 1.1 assessed using imaging scans (CT or MRI) and clinical assessment following 16 weeks of treatment.
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions", or similar definition as accurate and appropriate.
- Overall Response Rate Defined as Complete Response and Partial Response. [ Time Frame: Every 2 cycles (8 weeks) up to 2 years ]
The response to study treatment will be assessed after every 8 weeks (2 cycles) of therapy using CT or MRI scan images.Overall response rate will be measured per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT or MRI:
Complete response (CR) = disappearance of all target lesions. Partial Response (PR), = at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD.
- Clinical Benefit Rate as Defined by Complete Response, Partial Response and Stable Disease. [ Time Frame: Every 2 cycles (8 weeks) up to 2 years ]
The clinical benefit of study treatment will be assessed after 8 weeks (2 cycles) of therapy using scanning images (CT or MRI). Clinical benefit rate will be measured per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT or MRI:
Complete Response (CR) = disappearance of all target lesions. Partial Response (PR), = at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD.
Progressive Disease (PD) = At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.
Stable Disease (SD) = Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started.
- Overall Survival up to 2 Years Beyond Progression [ Time Frame: Time from the first dose of study treatment up to 2 years beyond disease progression ]Patients will be followed-up with from first dose of study drug up to 2 years following the date of disease progression.
- Number of Patients With 0-3 VEGFR1 and VEGFR2 Protein Expression and Time in Days on Treatment [ Time Frame: Tissue collected during screening process, prior to first treatment and response measured until 350 days. ]
Tissue from biopsy will be collected during screening and proteins (VEGFR1 and VEGFR2) will be evaluated to see if there is a correlation with patient response to treatment.
VERGFR = vascular endothelial growth factor receptor
To determine if there was a correlation between response to Tivozanib and VEGFR expression, immunohistochemical (IHC) analysis on archival tumor tissue was performed. We performed standard IHC and applied combined intensity score (from 0 to 3) for antigen expression and proportional score of 0-3 for the cells that were positive. For antigen expression, 0 was no staining, +1 being 1-25% staining, +2 being 26-50% staining and +3 being 50% or greater staining. Number of patients with VEGFR1 expression was correlated with time patients were on treatment in days.
- Treatment Toxicity as Measured by Adverse Events Experienced While on Treatment During Systematic Assessment. [ Time Frame: After every 4 weeks (1 cycle) until treatment discontinuation and up to a maximum of 2 years and 10 months. ]
Toxicity will be assessed after 4 weeks (1 cycle) and every 4 weeks during treatment according to the National Cancer Institute's Common Toxicity Criteria for adverse events version 4.0 (CTCAE v4.0). In general adverse events (AEs) will be graded according to the following:
Grade 1 Mild AE Grade 2 Moderate AE Grade 3 Severe AE Grade 4 Life-threatening or disabling AE Grade 5 Death related to AE
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:
|18 Years and older (Adult, Older Adult)
|Sexes Eligible for Study:
|Accepts Healthy Volunteers:
Inclusion Criteria:
- Patients must have histologically or cytologically confirmed sarcoma of soft tissue
- Patients must have metastatic and/or locally advanced or locally recurrent disease
- Patients must have measurable disease within 4 weeks prior to registration by RECIST 1.1, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >= 20 mm with conventional techniques or as >= 10 mm with spiral computed tomography (CT) scan; tumor lesions that are situated in a previously irradiated area may be considered measurable for the purposes of this study only if there is evidence of growth of the area following a course of irradiation that cannot be attributed to necrosis or bleeding into the tumor
- Patients must have had a minimum of 1 and a maximum of 4 prior chemotherapy regimens for recurrent/metastatic disease (it will be up to the treating investigator to define what constitutes a "regimen" in each case); the last dose of systemic therapy (include tyrosine kinase inhibitors) must have been given at least 4 weeks prior to initiation of therapy; patients receiving BCNU or mitomycin C must have received their last dose of such therapy at least 6 weeks prior to initiation of therapy
- Patients with brain metastasis that have been treated with definitive surgery or radiation and have been clinically stable for 3 months following the procedure with no neurological signs or symptoms and no requirement for systemic glucocorticoids are eligible for study
- Patients must exhibit an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Absolute neutrophil count >= 1.5 x 10^9/l
- Platelets >= 75 x 10^9/l
- Total bilirubin =< 1.5 x upper limit of normal (ULN) (except for patients with known Gilbert Syndrome)
- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional ULN
- Serum creatinine =< 1.5 x ULN
- If urine protein:creatinine (UPC) >= 1, then a 24-hour urine protein must be assessed; patients must have a 24-hour urine protein value < 1g to be eligible
- Patients must not have current evidence of another malignancy; there are no restrictions regarding prior history of malignancy
If female and of childbearing potential, documentation of negative pregnancy test is required within 7 days prior to first dose; sexually active males and females of childbearing potential must agree to use adequate contraceptive measures, while on study and for 30 days after the last dose of study drug; all subjects (and their partners) must agree to use a highly effective method of contraception; effective birth control includes (a) intrauterine device (IUD) plus one barrier method; or (b) 2 barrier methods; effective barrier methods are male or female condoms, diaphragms, and spermicides (creams or gels that contain a chemical to kill sperm)
- Note: oral, implantable, or injectable contraceptives may be affected by cytochrome P450 interactions, and are not considered effective for this study
- Adverse events related to prior tumor-specific therapy must have resolved to less than or equal to National Cancer Institute (NCI) Common Terminology Criteria of Adverse Events (CTCAE) (version 4) grade 1 prior to study entry (except alopecia)
Patients taking cytochrome P450 (CYP)3A4 inducers at the time of screening/registration are still eligible for participation, but whenever possible these medications should be discontinued or changed to one that is not an inducer
- NOTE: No washout period is required
- NOTE: It will be up to the treating investigator's discretion to assess whether or not the risk of discontinuing or changing the medication is higher or lower than the risk of continuing it while on study for the individual patient
- Patients must have the ability to understand and the willingness to sign a written informed consent document; signed and dated informed consent must be obtained prior to registration on trial
Exclusion Criteria:
- Patients with any one of the following sarcoma histological subtypes will not be eligible for participation: alveolar soft-part sarcoma, chondrosarcoma, dermatofibrosarcoma, Ewing sarcoma, gastrointestinal stromal tumor (GIST), Kaposi sarcoma, mixed mesodermal tumor/carcinosarcoma, osteosarcoma, and low grade (grade 1) sarcomas; NOTE: Myxoid liposarcoma with t(12;16) or t(22;22) is permitted; rhabdomyosarcoma (Embryonal, Alveolar, pleomorphic), interdigitating dendritic sarcoma, giant cell tumor of bone
- Patients who have had major surgery within 21 days or those who have not recovered from adverse events associated with surgery to =< grade 1 will not be eligible for participation; excluded from such considerations are surgical changes not expected to improve, e.g. removal of muscle tissue; patients may be on replacement glucocorticoids for pre-existing glucocorticoid deficiency (e.g. Addison's disease)
- Patients receiving any other investigational agents will not be eligible for participation
- Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to tivozanib will not be eligible for participation
Patients with serious and/or unstable pre-existing medical, psychiatric, or other conditions that could interfere with safety, provision of informed consent, or compliance to study procedures and requirements will not be eligible for participation, including but not limited to:
- Uncontrolled intercurrent illness
- Ongoing or active infection including HIV, active hepatitis B or C)
- Symptomatic congestive heart failure
- Unstable angina pectoris
- Cardiac arrhythmia
- Psychiatric illness/social situations that would limit compliance with study requirements will not be eligible for participation
- Pregnant women and women who are breast-feeding will not be eligible for participation
- Patients with a history or clinical evidence of central nervous system (CNS) metastases or leptomeningeal carcinomatosis will not be eligible for participation; NOTE: Individuals who have previously-treated CNS metastases, are asymptomatic, and have had no requirement for steroids or anti-seizure medications for 3 months prior to first dose of study drug are the exception; screening with CNS imaging studies such as CT or magnetic resonance imaging (MRI) is required only if clinically indicated or if the subject has a history of CNS metastases
Patients with clinically significant gastrointestinal (GI) abnormalities that may increase the risk for GI bleeding will not be eligible for participation; these include, but are not limited to:
- Active peptic ulcer disease
- Known intraluminal metastatic lesion/s with risk of bleeding
- Inflammatory bowel disease (e.g. ulcerative colitis, Crohn's disease), or other GI conditions with increased risk of perforation
- History of abdominal fistula, GI perforation, or intra-abdominal abscess within 28 days prior to beginning study treatment
- Clinically significant (> 1/2 teaspoon) hemoptysis or gastrointestinal hemorrhage in the past 6 months
- Patients with evidence of active bleeding or bleeding diathesis will not be eligible for participation; recent hemoptysis would be >= 1/2 teaspoon of red blood within 8 weeks before first dose of study drug
Patients with clinically significant GI abnormalities that may affect absorption of investigational product will not be eligible for participation; these include but are not limited to:
- Malabsorption syndrome
- Major resection of the stomach or small bowel
- Patients with a corrected QT interval (QTc) > 480 msecs using Bazett's formula (QT Interval / square root(RR interval)) will not be eligible for participation
Patients with left ventricular ejection fraction (LVEF) < 50% will not be eligible for participation
- NOTE: patients who do not meet the cutoff for LVEF may be re-screened at a later date and, if eligible then, may be enrolled in the study
Patients with a history of any one or more of the following cardiovascular conditions within the past 6 months will not be eligible for participation:
- Cardiac angioplasty or stenting
- Myocardial infarction
- Unstable angina
- Coronary artery bypass graft surgery
- Symptomatic peripheral vascular disease\
- Class III or IV congestive heart failure, as defined by the New York Heart Association (NYHA)
Patients with poorly controlled hypertension [defined as systolic blood pressure (SBP) of >= 140 mmHg or diastolic blood pressure (DBP) of >= 90mmHg] will not be eligible for participation
- Note: Initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry; following antihypertensive medication initiation or adjustment, blood pressure (BP) must be re-assessed three times at approximately 2-minute intervals; at least 24 hours must have elapsed between anti-hypertensive medication initiation or adjustment and BP measurement; these three values will be averaged to obtain the mean diastolic blood pressure and the mean systolic blood pressure; the mean SBP / DBP ratio must be < 140/90 mmHg in order for a subject to be eligible for the study
Patients with cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months will not be eligible for participation
- Note: subjects with recent DVT who have been therapeutically coagulated for at least 6 weeks are eligible
- Patients who had major surgery or trauma within 28 days prior to first dose of investigational product and/or presence of any non-healing wound, fracture, or ulcer (procedures such as catheter placement not considered to be major surgery) will not be eligible for participation
Patients with known endobronchial lesions and/or lesions infiltrating major pulmonary vessels will not be eligible for participation
- Note: tumor abutting the vessel is acceptable, but contiguous tumor and vessel is not; CT with contrast is strongly recommended to evaluate such lesions
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01782313
|United States, Illinois
|Northwestern University
|Chicago, Illinois, United States, 60611
|United States, Iowa
|University of Iowa
|Iowa City, Iowa, United States, 52246
|United States, Minnesota
|Mayo Clinic
|Rochester, Minnesota, United States, 55905
|United States, Missouri
|Washington University
|Saint Louis, Missouri, United States, 63110
|United States, Wisconsin
|University of Wisconsin
|Madison, Wisconsin, United States, 53792
|Principal Investigator:
|Mark Agulnik, MD
|Northwestern University
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
|Responsible Party:
|Mark Agulnik, Principal Investigator, Northwestern University
|ClinicalTrials.gov Identifier:
|NCT01782313 History of Changes
|Other Study ID Numbers:
NCI-2012-03188 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
STU00073826 ( Other Identifier: Northwestern University IRB# )
|First Posted:
|February 1, 2013 Key Record Dates
|Results First Posted:
|August 21, 2018
|Last Update Posted:
|September 18, 2018
|Last Verified:
|August 2018
Additional relevant MeSH terms:
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type


text:
The Detroit RiverFront Conservancy has named Hines Interests LP director Mark Wallace as its new president and CEO.
Wallace, 37, will join the conservancy in mid-August, succeeding former president and CEO Faye Alexander Nelson. She left in mid-February to become president of the DTE Energy Foundation and vice president of public affairs for Detroit-based DTE Energy Co.
At Hines, Wallace has supported development projects in Detroit, Chicago and Toronto over the past decade, including the first major portion of the Detroit RiverFront Conservancy's RiverWalk.
Most recently, he has served as the project manager of River Point, a 1.3 million-square-foot mixed-use development on the Chicago River that includes a public park and an extension of the city's famed Chicago River Walk.
Prior to that, Wallace managed Bayside, a 13-acre residential- and commercial-use waterfront development in Toronto that was funded through a public-private partnership.
He also served as leasing director of the GM Renaissance Center from 2007 to 2012, supported Wayne County's acquisition of the Guardian Building in 2006 and has overseen property management contracts for the city of Detroit's Coleman A. Young Municipal Center and Public Safety Headquarters.
Wallace holds bachelor's and master's degrees in public policy from Princeton University and the University of Michigan, respectively.
He is a director on the Boll Family YMCA board of directors and serves on the advisory boards of Kiva Detroit and Hatch Detroit.
Wallace was a member of the Crain's 40 under 40 Class of 2010.